title: Purification and characterization of a luminal cholecystokinin-releasing factor from rat intestinal secretion.
abstract: Cholecystokinin (CCK) secretion in rats and humans is inhibited by pancreatic proteases and bile acids in the intestine. It has been hypothesized that the inhibition of CCK release caused by pancreatic proteases is due to proteolytic inactivation of a CCK-releasing peptide present in intestinal secretion. To purify the putative luminal CCK-releasing factor (LCRF), intestinal secretions were collected by perfusing a modified Thiry-Vella fistula of jejunum in conscious rats. From these secretions, the peptide was concentrated by ultrafiltration followed by low-pressure reverse-phase chromatography and purified by reverse-phase high-pressure liquid chromatography. Purity was confirmed by high-performance capillary electrophoresis. Fractions were assayed for CCK-releasing activity by their ability to stimulate pancreatic protein secretion when infused into the proximal small intestine of conscious rats. Partially purified fractions strongly stimulated both pancreatic secretion and CCK release while CCK receptor blockade abolished the pancreatic response. Amino acid analysis and mass spectral analysis showed that the purified peptide is composed of 70-75 amino acid residues and has a mass of 8136 Da. Microsequence analysis of LCRF yielded an amino acid sequence for 41 residues as follows: STFWAYQPDGDNDPTDYQKYEHTSSPSQLLAPGDYPCVIEV. When infused intraduodenally, the purified peptide stimulated pancreatic protein and fluid secretion in a dose-related manner in conscious rats and significantly elevated plasma CCK levels. Immunoaffinity chromatography using antisera raised to synthetic LCRF-(1-6) abolished the CCK releasing activity of intestinal secretions. These studies demonstrate, to our knowledge, the first chemical characterization of a luminally secreted enteric peptide functioning as an intraluminal regulator of intestinal hormone release.
authors.affiliation: Department of Physiology, University of Texas Health Science Center, San Antonio 78284, USA.
authors.forename: A W
authors.initials: AW
authors.lastname: Spannagel
authors.forename: G M
authors.initials: GM
authors.lastname: Green
authors.forename: D
authors.initials: D
authors.lastname: Guan
authors.forename: R A
authors.initials: RA
authors.lastname: Liddle
authors.forename: K
authors.initials: K
authors.lastname: Faull
authors.forename: J R
authors.initials: JR
authors.lastname: Reeve
mesh_terms: D000595:Amino Acid Sequence; D000818:Animals; D001570:Benzodiazepinones / Q000494:pharmacology; D001681:Biological Assay; D002766:Cholecystokinin / Q000378:metabolism*; D002846:Chromatography, Affinity; D002851:Chromatography, High Pressure Liquid; D020109:Devazepide; D004386:Duodenum / Q000502:physiology*; D006727:Hormone Antagonists / Q000494:pharmacology; D007413:Intestinal Mucosa / Q000502:physiology*; D007583:Jejunum / Q000502:physiology*; D008297:Male; D013058:Mass Spectrometry; D008969:Molecular Sequence Data; D010189:Pancreatic Juice / Q000187:drug effects / Q000378:metabolism; D011506:Proteins / Q000737:chemistry / Q000302:isolation & purification* / Q000494:pharmacology*; D051381:Rats; D017208:Rats, Wistar; D015203:Reproducibility of Results
chemical_list: D001570:Benzodiazepinones; D006727:Hormone Antagonists; D011506:Proteins; D002766:Cholecystokinin; D020109:Devazepide